Sep 21, 2022 | Glass Pharms
LONDON, Sept. 21, 2022 /PRNewswire/ — Having secured up to £26.7M of funding from a FTSE-250 listed investment fund, Glass Pharms, the UK-based medical cannabis cultivation company, are delighted to announce a team of best-of-breed partners to complete their...
